Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 14;10(3):e004223. doi: 10.1136/jitc-2021-004223

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Immunohistochemistry analysis of T cell infiltration in (A) itacitinib plus epacadostat treatment samples (n=12), (B) itacitinib plus high-dose parsaclisib (1–10 mg) treatment samples (n=9; only 8 samples were available for TIL response assessment, since 1 sample failed FoxP3 analysis), and (C) itacitinib plus low-dose parsaclisib (0.3 mg) treatment samples (n=12). Comparisons were performed using Wilcoxon matched-pairs signed-rank test; changes were deemed significant at p<0.05. TIL responder was defined as ≥50% increase in the CD8⁺ to FoxP3⁺ cell ratio in the tumor compartment post-treatment versus baseline, as determined by immunohistochemistry. FoxP3, forkhead box protein 3; NS, not significant; TIL, tumor-infiltrating lymphocyte.